Global Still’s Disease Treatment Market to Reach Up To US$ 2,093.8 Million by end of 2027, Says Coherent Market Insights

SEATTLE–(BUSINESS WIRE)–#PainManagement–According to Coherent Market Insights, the global Still’s disease treatment market is estimated to be valued at US$ 1,539.4 million in 2020 and is expected to exhibit a CAGR of 4.49% during the forecast period (2020-2027).

Key Trends and Analysis:

The global still’s disease treatment market is expected to witness significant growth, owing to increasing research & development activities and drug launches. For instance, in July 2018, Swedish Orphan Biovitrum AB launched Kineret drug for the treatment of AOSD (adult-onset still’s disease). Kineret (anakinra) is a third-line treatment for use when still’s disease does not respond to DMARDs and corticosteroids, and when patients fail to respond to methotrexate. For rheumatoid (RA) and CAPS, this drug is already available in the U.K.

In June 2020, Novartis Pharmaceuticals Corporation launched Ilaris injection post receiving FDA approval for the treatment of Still’s disease. In 2018, this injection was approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older. This drug is also used for the treatment of Adult-Onset Still’s Disease (AOSD). Such introductions would, in turn, establish a platform for the market development, driving the industry growth.

Key players in the still’s disease treatment market are focused on strategic license agreements and joint ventures to maintain a competitive edge in the market. For instance, in July 2019, Aevi Genomic Medicine and AstraZeneca entered into a license agreement for its fully human mAb MEDI2338 phase II trials that target IL-18 (interleukin 18). Aevi Genomic planned to initially develop the drug for AOSD (adult-onset Still’s disease).

(Read more…)

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/4023

Key Market Takeaways:

The global still’s disease treatment market is expected to exhibit a CAGR of 4.49% during the forecast period (2020-2027), owing to increasing prevalence of still’s disease across the world. For instance, according to the Swedish Orphan Biovitrum AB, the prevalence of Still’s disease is around 25,000 in the European Union, each year.

Europe is expected to be the most lucrative region in the global still’s disease treatment market, owing to drug approvals in the region. For instance, in April 2018, SOBI announced that Kineret (anakinra) received approval from the European Commission (EC) for Still’s disease treatment.

Key players operating in the global still’s disease treatment market include Swedish Orphan Biovitrum AB, AB2 Bio Ltd., Fresenius Kabi AG, F. Hoffmann-La Roche Ltd, Dr Reddy’s Laboratories Ltd., Novartis AG, Amneal Pharmaceuticals LLC, Jubilant Life Sciences Ltd, Zydus Cadila, Sun Pharmaceutical Industries Ltd, Vintage Labs, Horizon Therapeutics plc, Hikma Pharmaceuticals PLC, Mylan N.V., and Teva Pharmaceutical Industries Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4023

Market Segmentation:

• Global Still’s Disease Treatment Market, By Treatment:
  • Pain Management
  • Corticosteroids Therapy
  • Tocilizumab
  • Canakinumab
  • Anakinra
  • Others
• Global Still’s Disease Treatment Market, By Route of Administration:
  • Injectable
  • Oral
• Global Still’s Disease Treatment Market, By Distribution Channel:
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• Global Still’s Disease Treatment Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa

Related Market Intelligence Report:

Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid, Others), Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospitals Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, China, Middle East & Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/global-and-china-osteoporosis-drugs-market-4018

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter